Next Article in Journal
Metabolic Response to XD14 Treatment in Human Breast Cancer Cell Line MCF-7
Next Article in Special Issue
Melatonin: A Mitochondrial Targeting Molecule Involving Mitochondrial Protection and Dynamics
Previous Article in Journal
Trans-Stilbenes in Commercial Grape Juices: Quantification Using HPLC Approaches
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(10), 1771; doi:10.3390/ijms17101771

Melatonin as a Potential Agent in the Treatment of Sarcopenia

1
Department of Morphology and Cellular Biology, Medicine Faculty, University of Oviedo, Julian Claveria, s/n, Oviedo 33006, Spain
2
Department of Cellular and Structural Biology, UTHSCSA, San Antonio, TX 78229, USA
3
Service of Microbiology, Hospital Universitario Central de Asturias, Avenida de Roma, s/n, Oviedo 33011, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Charles J. Malemud
Received: 15 September 2016 / Revised: 17 October 2016 / Accepted: 17 October 2016 / Published: 24 October 2016
(This article belongs to the Special Issue Melatonin and Its Analogues: Experimental and Clinical Aspects)
View Full-Text   |   Download PDF [663 KB, uploaded 24 October 2016]   |  

Abstract

Considering the increased speed at which the world population is aging, sarcopenia could become an epidemic in this century. This condition currently has no means of prevention or treatment. Melatonin is a highly effective and ubiquitously acting antioxidant and free radical scavenger that is normally produced in all organisms. This molecule has been implicated in a huge number of biological processes, from anticonvulsant properties in children to protective effects on the lung in chronic obstructive pulmonary disease. In this review, we summarize the data which suggest that melatonin may be beneficial in attenuating, reducing or preventing each of the symptoms that characterize sarcopenia. The findings are not limited to sarcopenia, but also apply to osteoporosis-related sarcopenia and to age-related neuromuscular junction dysfunction. Since melatonin has a high safety profile and is drastically reduced in advanced age, its potential utility in the treatment of sarcopenic patients and related dysfunctions should be considered. View Full-Text
Keywords: melatonin; sarcopenia; frailty; skeletal muscle; aging melatonin; sarcopenia; frailty; skeletal muscle; aging
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Coto-Montes, A.; Boga, J.A.; Tan, D.X.; Reiter, R.J. Melatonin as a Potential Agent in the Treatment of Sarcopenia. Int. J. Mol. Sci. 2016, 17, 1771.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top